AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Insilico Medicine vs Atomwise

Insilico Medicine

Enterprise

Visit Website Full Review

Atomwise

Enterprise

Visit Website Full Review

Verdict by Category

Detailed category analysis is not available for this comparison.

View Insilico Medicine View Atomwise

Feature & Spec Matrix

Detailed Comparison23 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features

Feature / Spec

Insilico Medicine

Atomwise

Pricing Model

EnterpriseCustom Enterprise Biotech / Pharma Licensing for PandaOmics, Chemistry42, and inClinico — Partnership inquiry

EnterpriseAtomwise operates through enterprise partnership and co-development agreements — there is no self-serve access or published pricing. Collaboration types include: sponsored research agreements (pharma/biotech pays Atomwise to run AI-powered hit discovery campaigns), co-development partnerships (shared IP and milestone/royalty structures), and academic program access for universities through the ATOM initiative. New CEO Steve Worland is also steering Atomwise toward an internal proprietary drug pipeline, which will generate revenue through future licensing and partnering deals as candidates mature into preclinical and clinical stages. Contact Atomwise through atomwise.com for partnership and collaboration inquiries.

Starting Price

Custom / Contact Sales

Free Plan & Trial Scope

Difference

No free access — platform licensing and drug discovery collaborations via enterprise agreements

No free plan — enterprise and academic collaboration agreements via sales/partnership team

User Rating Score

Unrated

Ideal Workflow / Use Case

Difference

Pharmaceutical companies and biotechs seeking to accelerate drug discovery from target identification to clinical prediction using generative AI and automated chemistry

Pharmaceutical and biotech R&D teams needing AI-powered virtual screening and hit discovery against novel, difficult, or undruggable disease targets at industrial scale

Enterprise & Scalability

Difference

Pharma.AI platform available for licensing and collaboration agreements with major pharma companies; HKEX listed (3696); regulatory filings in multiple jurisdictions; automated robotic lab integration; multi-country R&D centers

Enterprise pharma collaboration agreements; 250+ partner network; custom research contracts with major pharmaceutical, agrochemical, and biotech companies; academic partnership program for universities including Harvard, Stanford, and Duke

Core Categories

AI Healthcare ToolsAI Research & Education Tools

Pharma.AI end-to-end platform: PandaOmics (target ID), Chemistry42 (molecule design), InClinico (clinical prediction)

Difference

Insilico Medicine Advantage

Not listed

Rentosertib (ISM001-055) — world's most advanced fully AI-discovered drug in Phase 3 for IPF

Supported

31+ drug programs across 29 targets in cancer, fibrosis, CNS, immunity, and aging

Supported

Generative AI for de novo molecule design against novel and known drug targets

Supported

Automated robotic laboratory in Suzhou connected directly to the AI platform

Difference

Insilico Medicine Advantage

Not listed

300+ patents filed, 200+ peer-reviewed publications in top scientific journals

Difference

Insilico Medicine Advantage

Not listed

Multi-billion dollar licensing partnerships with Sanofi, Fosun Pharma, and Exelixis

Supported

Chemistry42 generative AI designs novel molecules not found in existing chemical libraries

Difference

Insilico Medicine Advantage

Not listed

PandaOmics AI for target identification using multi-omics, literature, and clinical data

Difference

Insilico Medicine Advantage

Not listed

Listed on Hong Kong Stock Exchange (HKEX: 3696) — founded 2014 at Johns Hopkins University

Difference

Insilico Medicine Advantage

Not listed

185+ completed projects validated across diverse protein types including undruggable targets

Difference

Not listed

Atomwise Advantage

Foundation Model for molecular discovery — next-generation AI announced at TRANSONC 2026

Difference

Not listed

Atomwise Advantage

AIDDISON platform for structure-based hit discovery and lead optimization

Difference

Not listed

Atomwise Advantage

Co-development agreements with major pharma — Merck, and 4 of top 10 US pharmaceutical companies

Difference

Not listed

Atomwise Advantage

Academic ATOM program: collaborations with 40+ universities including Harvard, Stanford, and Duke

Difference

Not listed

Atomwise Advantage

Founded 2012 — pioneered deep learning in drug discovery; $226M+ total raised

Difference

Not listed

Atomwise Advantage

Insilico Medicine Pros & Cons

Pros

World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
Automated robotic lab in Suzhou closing the loop between AI design and physical testing
Global presence: US, China, Canada, Middle East — with partnerships across big pharma
Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing

Cons

Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
Dual-track model (platform + internal pipeline) adds operational complexity
Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
Listed on HKEX (Hong Kong) — less accessible to US institutional investors

Atomwise Pros & Cons

Pros

Invented deep learning for structure-based drug discovery in 2012 — true pioneer in the field
AtomNet screens 16B+ compounds in under 2 days — fastest virtual screening at this scale
775+ collaborations and 250+ partners — most validated partnership network in AI drug discovery
Tackles undruggable targets that traditional methods can't address
Strong academic program: 40+ universities including Harvard, Stanford, and Duke
New Foundation Model announced 2026 — next-generation AI for molecular discovery
$226M+ raised from DCVC, Khosla, Y Combinator, Tencent, B Capital, and Baidu

Cons

Early-stage company — no FDA-approved drugs from the platform yet
Shifting focus from platform licensing to proprietary pipeline adds execution risk
Smaller team (~100-250 employees) compared to larger AI drug discovery peers
Revenue still modest at $5-25M range — pre-commercial stage
Deep tech focus means long timelines before patient impact is realized

Head-to-Head Battle Cards